Studies are underway that may lead the FDA to stiffen its bioequivalence rules for generic anti-epileptic drugs (AEDs). Dr. Michael Privitera, a neurologist at the UC Gardner Neuroscience Institute’s Epilepsy Center, explains that after some hesitation the FDA has agreed that studies are necessary.
Media Outlet:
Med Page Today
